Velos releases new iPad app for clinicians in oncology, bone marrow …News-Medical.netVelos, Inc. today announced the release of Velos Aversi, an iPad app for clinicians in oncology and bone marrow transplantation. The app is now available for downloa…
Indiana University School of Medicine scientists have successfully transplanted primary kidney cells intravenously to treat renal failure in rats, pointing the way to a possible future alternative to kidney transplants and expensive dialysis treatments…
COLUMN: Ghost hunting is not history and shouldn't be on History ChannelOklahoma DailyFinally, I don't believe in ghosts because I don't believe that a person can survive brain death in any fashion. A ghost's existence implies that a no…
/C O R R E C T I O N — Veloxis Pharmaceuticals A/S/Sacramento BeeThis subgroup analysis suggests that African Americans experience similar clinical results on LCP-Tacro, once-daily, as with twice-daily tacrolimus and there is evidence to suggest a low…
Some Top-Rated Stocks Set Up As Market FallsInvestor’s Business DailyAlexion Pharmaceuticals (ALXN), whose specialty is treatments for cancer, auto-immunity disorders and transplant rejection, has built a 10-week base. The base shows a correction of ju…
In the news release, Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro™ in Stable African-American Kidney Transplant Patients at American Transplant Congress …
Bride to be giving groom gift of life Today, May 31, 2012.
Indiana University School of Medicine scientists have successfully transplanted primary kidney cells intravenously to treat renal failure in rats, pointing the way to a possible future alternative to kidney transplants and expensive dialysis treatments…
HORSHOLM, Denmark, May 31, 2012 /PRNewswire/ — Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests th…
Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of …MarketWatch (press release)This subgroup analysis suggests that African Americans experience similar clinical results on LCP-Tacro, once-daily, as with twice-daily tacrol…